108.86
-2(-1.80%)
Currency In USD
| Previous Close | 110.86 |
| Open | 110.18 |
| Day High | 112.25 |
| Day Low | 108.03 |
| 52-Week High | 139.13 |
| 52-Week Low | 64.11 |
| Volume | 535,100 |
| Average Volume | 865,468 |
| Market Cap | 5.36B |
| PE | -18.87 |
| EPS | -5.77 |
| Moving Average 50 Days | 114.3 |
| Moving Average 200 Days | 99.52 |
| Change | -2 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) since IPO date, it would be worth $12,455.38 as of May 09, 2025 at a share price of $108.86. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $1,219.72 as of May 09, 2025 at a share price of $108.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
GlobeNewswire Inc.
May 01, 2025 11:00 AM GMT
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
GlobeNewswire Inc.
Apr 08, 2025 11:00 AM GMT
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results fo
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
GlobeNewswire Inc.
Apr 04, 2025 11:00 AM GMT
Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation Presentation featuring network meta-analysis of SYMBRAVO® versus oral CGRPs NEW YORK, April 04, 2025 (GLOBE NEWSW